First Look At FMED: Poor Performance Merits A Strong Sell Rating
Source: SeekingAlpha
2025-05-05 12:12:44 ET
Summary
- Fidelity Disruptive Medicine ETF invests in innovative healthcare companies, focusing on sectors like robotic surgery, genomics, and advanced diagnostics, aiming to disrupt traditional medical practices.
- The ETF employs a bottom-up stock picking approach, benchmarking against the MSCI ACWI Index and MSCI All Country World Healthcare Equal Weighted Index.
- Based on the results so far, this strategy has been a dud, earning this ETF another Strong Sell rating for this series of ETFs.
- Investors should evaluate if the ETF's disruptive holdings align with their investment goals and compare its performance against standard industry ETFs for a Buy decision.
Introduction
Read the full article on Seeking Alpha
For further details see:
First Look At FMED: Poor Performance Merits A Strong Sell Rating
Fidelity Disruptive Medicine ETF
NASDAQ: FMED
FMED Trading
-1.85% G/L:
$24.92 Last:
3,656 Volume:
$24.90 Open:
